Evidence map›Paper›PMID 27270433›Full record

ArticleOncogene2017

A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

L A Selth, R Das, S L Townley, I Coutinho, A R Hanson, M M Centenera, N Stylianou, K Sweeney, C Soekmadji, L Jovanovic and 7 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03176381 (Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC), which is not on this map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03176381 completednot on this map

Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC

TypeobservationalSponsorTianjin Medical University Second HospitalRan2017 to 2023Enrolled110ConditionsMetastatic Castration-resistant Prostate Cancer
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Urinary microRNAs expression in prostate cancer diagnosis: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Urinary miRNAs: Technical Updates.MicroRNA (Shariqah, United Arab Emirates) · 2024
    Review
  13. Roles of exosome-derived non-coding RNA in tumor micro-environment and its clinical application.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. miRNA-mediated control of exogenousMolecular therapy. Methods & clinical development · 2022
    Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 2 countries.

L A SelthDame Roma Mitchell Cancer Research Laboratories, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
R DasDame Roma Mitchell Cancer Research Laboratories, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
S L TownleyDame Roma Mitchell Cancer Research Laboratories, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
I CoutinhoDame Roma Mitchell Cancer Research Laboratories, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
A R HansonDame Roma Mitchell Cancer Research Laboratories, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
M M CenteneraFreemasons Foundation Centre for Men's Health, Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
N StylianouAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
K SweeneyAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
C SoekmadjiAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
L JovanovicAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
C C NelsonAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
A ZoubeidiThe Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Australia.
L M ButlerFreemasons Foundation Centre for Men's Health, Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
G J GoodallDiscipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
B G HollierAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
P A GregoryDiscipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
W D TilleyDame Roma Mitchell Cancer Research Laboratories, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
The University of Adelaide · AUFreemasons Foundation Centre for Men's Health · AUPrincess Alexandra Hospital · AUQueensland University of Technology · AUTranslational Research Institute · AUSouth Australian Health and Medical Research Institute · AUSouth Australia Pathology · AUThe Prostate Centre · GBUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA-375 (miR-375) is frequently elevated in prostate tumors and cell-free fractions of patient blood, but its role in genesis and progression of prostate cancer is poorly understood. In this study, we demonstrated that miR-375 is inversely correlated with epithelial-mesenchymal transition signatures (EMT) in clinical samples and can drive mesenchymal-epithelial transition (MET) in model systems. Indeed, miR-375 potently inhibited invasion and migration of multiple prostate cancer lines. The transcription factor YAP1 was found to be a direct target of miR-375 in prostate cancer. Knockdown of YAP1 phenocopied miR-375 overexpression, and overexpression of YAP1 rescued anti-invasive effects mediated by miR-375. Furthermore, transcription of the miR-375 gene was shown to be directly repressed by the EMT transcription factor, ZEB1. Analysis of multiple patient cohorts provided evidence for this ZEB1-miR-375-YAP1 regulatory circuit in clinical samples. Despite its anti-invasive and anti-EMT capacities, plasma miR-375 was found to be correlated with circulating tumor cells in men with metastatic disease. Collectively, this study provides new insight into the function of miR-375 in prostate cancer, and more broadly identifies a novel pathway controlling epithelial plasticity and tumor cell invasion in this disease.

Indexed as

Gene Expression Regulation, NeoplasticSignal Transduction3' Untranslated RegionsAdaptor Proteins, Signal TransducingAnimalsBiomarkersCell Line, TumorEpithelial-Mesenchymal TransitionEpitheliumGene ExpressionHumansMaleMicroRNAsNeoplastic Cells, CirculatingPhenotypePhosphoproteins3' Untranslated RegionsAdaptor Proteins, Signal TransducingBiomarkersMicroRNAsMIRN375 microRNA, humanPhosphoproteinsProto-Oncogene Proteins c-metTranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsZinc Finger E-box-Binding Homeobox 1

Identifiers

PMID27270433
OpenAlexW2414333934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.